Full briefing — the morning intelligence for investors and analysts:
https://burns-media.com/biotech/archive/2026-05-08?utm_source=mastodon&utm_medium=social&utm_campaign=biotech_daily

Free. Delivered by 7 AM ET, every weekday.

#Biotech #FDA #Pharma #ClinicalTrials

Angelini's $4B Catalyst Deal Expands CNS Portfolio

Angelini Pharma is acquiring Catalyst Pharmaceuticals for $4 billion, significantly enhancing its portfolio in rare CNS disorders. This deal positions…

Burns Media
Venom and Hot Peppers Offer a Key to Killing Resistant Bacteria

Researchers have developed three new antibiotics from scorpion venom and habanero peppers to combat tuberculosis and other drug-resistant pathogens.

WIRED
if you're looking for an impactful #science based #investing opportunity, i have some slides to show you :) #biotech #medicine #neurodegeneration #CNS

What the hell is happening in China?

2026년 중국 바이오텍 산업은 초기 단계 자산 공급 증가로 인해 서구 바이오텍의 단순 모방 신약 개발이 어려워지고 있으며, 중국 내 제약사들이 직접 자산을 확보하면서 중개자 역할이 줄어들고 있다. 중국 바이오텍은 다수 후보물질을 보유하는 포트폴리오 전략으로 파트너십 가능성을 높이고 있으며, 임상시험은 중국 내 제조 없이도 가능하다. IP 보호에 대한 오해가 많으며, 중국 시장 특성상 미국 시장 진출이 필수적이다. 또한, 중국 내 연구자 주도 임상시험(IIT)이 빠르고 저렴한 데이터 확보 수단으로 자리잡고 있으며, FDA가 IIT 데이터를 IND 제출에 인정하는 사례도 증가하고 있다.

https://ladanuzhna.xyz/writing/what-is-happening-in-china/

#biotech #china #clinicaltrials #ipprotection #iit

What the hell is happening in China?

Full briefing — the morning intelligence for investors and analysts:
https://burns-media.com/biotech/archive/2026-05-07?utm_source=mastodon&utm_medium=social&utm_campaign=biotech_daily

Free. Delivered by 7 AM ET, every weekday.

#Biotech #FDA #Pharma #ClinicalTrials

Angelini's $4.1B Catalyst Buyout Expands Neurology Reach

Angelini Pharma is acquiring Catalyst Pharmaceuticals for $4.1 billion, significantly enhancing its neurology portfolio with three FDA-approved…

Burns Media

For Every Patient Their Own Drug

Stan Crooke 박사는 희귀 유전 질환 환자들을 위해 맞춤형 약물을 설계하는 데 평생을 바쳐왔다. 그는 항감각 올리고뉴클레오티드(ASO) 기술을 기반으로 한 신약 개발에 선구자적 역할을 했으며, Ionis Pharmaceuticals를 설립해 Spinraza 등 혁신적인 치료제를 상용화했다. 최근에는 개별 환자 맞춤형 치료를 목표로 하는 n-Lorem 재단에서 희귀 질환 환자들을 위한 신약 개발을 이어가고 있다. 그의 연구는 희귀 질환 치료제 개발과 개인 맞춤형 의학 분야에 중요한 기여를 하고 있다.

https://nautil.us/for-every-patient-their-own-drug-1280433

#antisense #drugdevelopment #raredisease #personalizedmedicine #biotech

For Every Patient Their Own Drug

For Every Patient Their Own Drug: Patients with exceedingly rare genetic diseases fall through the cracks of the medical system. This doctor is designing drugs for them, one at a time.

Massachusetts biotech leaders join the American Biotech Innovation Alliance to preserve US dominance amid China's rapid progress in the sector, highlighting a new push for national cohesion in innovation.

#usa #geopolitics #biotech #chinacompetition https://geopolitiq.com/post/us-biotech-firms-form-alliance-to-counter-china-s-advance-mov16aan?utm_source=mastodon&utm_medium=social&utm_campaign=auto_repost

📰 BIOTECH CATALYST

CellCentric Raises $220M to Advance Multiple Myeloma Treatment

This financing comes as the company aims to address treatment…

In today's briefing →
https://burns-media.com/biotech/archive/2026-05-06?utm_source=mastodon&utm_medium=social&utm_campaign=biotech_resurface

#Biotech #FDA

Scharfe Kritik nach Standortschließungen bei Biontech.

Die Entscheidung von BioNTech, mehrere Standorte zu schließen, sorgt für heftige Reaktionen. Besonders im Fokus steht dabei das ehemalige Werk des Konkurrenten CureVac in Tübingen. Dort sollen hunderte Arbeitsplätze wegfallen. Insgesamt könnten bis zu 1860 Stellen betroffen sein.

https://t1p.de/ohfs5

#Biontech #Curevac #Pharma #Biotech #Stellenabbau #Jobs #Deutschland #Tübingen #Wirtschaft #mRNA #Forschung #Impfstoff #Corona

Full briefing — the morning intelligence for investors and analysts:
https://burns-media.com/biotech/archive/2026-05-06?utm_source=mastodon&utm_medium=social&utm_campaign=biotech_daily

Free. Delivered by 7 AM ET, every weekday.

#Biotech #FDA #Pharma #ClinicalTrials

Bayer to acquire Perfuse Therapeutics for $300M

Bayer is set to acquire Perfuse Therapeutics for $300 million, focusing on mid-stage treatments for blindness. This marks Bayer's first significant…

Burns Media